Sep 17, 2020 | Webinar

Invitation to webinar on NMIBC follow-up

Nucleix, Israel and Oncotest-Rhenium, Israel are pleased to invite you to the webinar “Follow-up of NMIBC, Including the Place of Urinary Markers”, led by Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands.

The webinar will discuss follow-up of Non-Muscle-Invasive Bladder Cancer (NMIBC) and the position of urine biomarkers, and will be held in English.

Time: Thursday, 24 September 2020, from 20.00-21.00 PM Israeli time / 19.00-20.00 PM CEST.

The webinar will start with a 45 minutes lecture, and the last 15 minutes will be dedicated to a Q&A session.

Registration is free: https://zoom.us/meeting/register/tJcpdeCvqDojHdXOndQdiOUqVK7nZd6Uj_sF

If you are unable to attend, the webinar will be recorded and will become available on this platform afterwards.

Register here

Share this on your favourite network:

All updates

Other updates

The diagnostic value of urinary biomarkers in UTUC

Feb 2, 2024 | Publication

Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...

Including Bladder EpiCheck® in NMIBC surveillance leads to a major reduction in healthcare costs

Jan 19, 2024 | Publication

Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...

Henry with intermediate-risk NMIBC finds follow-up cystoscopies burdensome. What now?

Jun 30, 2023 | Clinical case

Henry, 70 years old, used to work as a creative director in a chocolate factory. Once, he designed chocolates that looked like broccoli. Too bad, they were not favoured by the clients … He was initially diagnosed with a solitary small Ta low-grade (LG) tumour. He...